Distinct pituitary hormone levels of 184 Chinese children and adolescents with multiple pituitary hormone deficiency: a single-centre study

Background Pituitary tumors and/or their treatment are associated with multiple pituitary hormone deficiency (MPHD) in adults, but the distinct pituitary hormone profile of MPHD in Chinese children and adolescents remains unclear. Methods Patients with MPHD were divided into four groups according to their MRI results: 1) pituitary stalk interruption syndrome (PSIS); 2) hypoplasia; 3) normal; and 4) tumor survivor. Results Among the 184 patients, 93 patients (50.5%) were with PSIS, 24 (13.0%) had hypoplastic pituitary gland, 10 (5.4%) patients were normal, and 57 (31.0%) were tumor survivors. There was an association between abnormal fetal position and PSIS (P <= 0.001). The CA/BA in PSIS, hypoplasia, normal, tumor survivor groups were 2.27 +/- 1.05, 1.48 +/- 0.39, 1.38 +/- 0.57, 1.49 +/- 0.33, and HtSDS were - 3.94 +/- 1.39, - 2.89 +/- 1.09, - 2.50 +/- 1.05, - 1.38 +/- 1.63. Patients in PSIS group had the largest CA/BA (P <= 0.001 vs. hypoplasia group, P = 0.009 vs. normal group, P <= 0.001 vs. tumor survivors) and lowest HtSDS (P <= 0.001 vs. hypoplasia group, P = 0.003 vs. normal group, P <= 0.001 vs. tumor survivors). The levels of TSH in the PSIS, hypoplasia, normal, and tumor survivor groups were 1.03 +/- 1.08 (P = 0.149 vs. tumor survivors), 1.38 +/- 1.47 (P = 0.045 vs. tumor survivors), 2.49 +/- 1.53 (P < 0.001 vs. tumor survivors), and 0.76 +/- 1.15 mu IU/ml. The levels of GH peak in PSIS, hypoplasia, normal, tumor survivor groups were 1.37 +/- 1.78, 1.27 +/- 1.52, 3.36 +/- 1.79, 0.53 +/- 0.52 ng/ml and ACTH were 27.50 +/- 20.72, 25.05 +/- 14.64, 34.61 +/- 59.35, 7.19 +/- 8.63 ng/ml. Tumor survivors had the lowest levels of GH peak (P <= 0.001 vs. PSIS group, P = 0.002 vs. hypoplasia group, P <= 0.001 vs. normal group) and ACTH (all the P <= 0.001 vs. the other three groups). Conclusion The frequency of PSIS is high among children and adolescents with MPHD. The severity of hormone deficiencies in patients with MPHD was more important in the tumor survivor group compared with the other groups.